Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ledipasvir (GS-5885) is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.
ターゲット&IC50 | NS5A (1b replicon):4 pM(EC50), NS5A (1a replicon):34 pM(EC50) |
In vivo | Ledipasvir distinguishes itself not only for its substantial replicon potency but also for its low clearance, high bioavailability, and extended half-lives across several species (rat, dog, and monkey) alongside a low predicted clearance in humans. Its pharmacokinetics have been assessed in rats and dogs, demonstrating favorable plasma half-lives (rat 1.83 ± 0.22 hr, dog 2.63 ± 0.18 hr), minimal systemic clearance (CL), and moderate distribution volumes (Vss) exceeding total body water volume[1]. |
別名 | GS-5885 |
分子量 | 889 |
分子式 | C49H54F2N8O6 |
CAS No. | 1256388-51-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (104.6 mM)
Ethanol: 93 mg/mL (104.6 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ledipasvir 1256388-51-8 Microbiology/Virology Proteases/Proteasome HCV Protease SARS-CoV inhibit HCV Inhibitor SARS coronavirus GS-5885 GS 5885 GS5885 Hepatitis C virus inhibitor